Vancouver, BC, Canada, January 12, 20201, Xebra Brands Ltd. (“Xebra”) is pleased to report that Mexico’s Ministry of Health has officially adopted regulations for the production, research, and sale of medicinal cannabis for pharmaceutical applications.

The latest revisions consist of secondary regulations to the 2017 General Health Law, which allows for the use of cannabinoids and cannabis derivates for medicinal purposes.

Pursuant to the regulations, companies interested in researching cannabis for pharmaceutical applications must obtain the authorization of the COFEPRIS (the Mexican FDA equivalent).

Pharmaceutical drugs containing cannabis derivates will require a prescription issued by an authorized physician; pharmacies will require a permit and must create a patient register. Advertising is limited to health professionals. Cannabis cultivation for pharma applications is allowed, and imports to create pharmaceutical drugs will be allowed, but the export of Mexican-grown cannabis is prohibited under these regulations.

The Mexican government is aiming to introduce a comprehensive federal legal framework for recreational cannabis legalization by April 30 of this year. Once in effect, Mexico would become the world’s largest cannabis market.

For more information contact:

+1 (604) 418-6560
[email protected]